Local control in advanced cancer of the nasopharynx: Is a boost dose by endocavitary brachytherapy of prognostic significance?

Levendag, Peter C.; Keskin-Cambay, Fatma; Pan, Connie de; Idzes, M.H.M.; Wildeman, Maarten A.; Noever, Inge; Kolkman-Deurloo, I.K.K.; Al‐Mamgani, Abrahim; El-Gantiry, M.; Rosenblatt, Eduardo; Teguh, David N.

doi:10.1016/j.brachy.2012.06.001

Cited by 27 publications

(25 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intracavitary brachytherapy for nasopharyngeal tumors has resulted in excellent results in early cases in which the local tumor extension can be adequately encompassed within the prescription isodose [4,18]. The Rotterdam group reported significant differences in local control between patients treated with or without a brachytherapy boost in the pooled analysis for T1-T2 N+ cases, thus confirming the results of other investigators with early local disease [46,47]. Larger tumors are nowadays better suited with high-precision external techniques although the development of endoscopically-guided intracavitary-interstitial devices may extend the brachytherapy indications for this location [48,49].…”

Section: Nasopharyngeal Cancersupporting

confidence: 63%

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

Kovács

Martı́nez-Monge

Budrukkar

et al. 2017

Radiotherapy and Oncology

124

View full text Add to dashboard Cite

The Head and Neck Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology) published in 2009 the consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy in head & neck cancers. The use of brachytherapy in combination with external beam radiotherapy and/or surgery was also covered as well as the use of brachytherapy in previously irradiated patients. Given the developments in the field, these recommendations needed to be updated to reflect up-to-date knowledge. The present update does not repeat basic knowledge which was published in the first recommendation but covers in a general part developments in (1) dose and fractionation, (2) aspects of treatment selection for brachytherapy alone versus combined BT+EBRT and (3) quality assurance issues. Detailed expert committee opinion intends to help the clinical practice in lip-, oral cavity-, oropharynx-, nasopharynx-, and superficial cancers. Different aspects of adjuvant treatment techniques and their results are discussed, as well the possibilities of salvage brachytherapy applications.

show abstract

Section: Nasopharyngeal Cancersupporting

confidence: 63%

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

Kovács

Martı́nez-Monge

Budrukkar

et al. 2017

Radiotherapy and Oncology

124

View full text Add to dashboard Cite

show abstract

“…Already in 1982 Ibrahim et al [12] presented their experience with carcinoma of the nasal vestibule, reporting on very satisfactory levels of local tumour control. Brachytherapy has also been applied with satisfying results to patients with locally persistent/recurrent and locally extensive lesions of the nasopharynx [13][14][15][16][17]. In our collection, 2 patients were treated with brachytherapy for recurrent disease.…”

Section: Discussionmentioning

confidence: 98%

Customized individual applicators for endocavitary brachytherapy in patients with cancers of the nasal cavity, sinonasal region and nasopharynx

Kadah

Niewald

Papaspyrou

et al. 2015

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Brachytherapy has become an established therapeutic regimen for primary, persistent, recurrent and metastatic tumour disease in the head and neck region. This study presents the authors' preliminary experience with intracavitary brachytherapy by means of an individual silicone applicator in the treatment of patients with nasal, sinonasal, orbital and nasopharyngeal cancer. Between January 2001 and January 2013, twenty patients with cancer of the nasal cavity, the paranasal sinuses and nasopharynx underwent surgery and intracavitary brachytherapy with the aid of an individually manufactured silicone applicator in the Department of Otolaryngology, Head and Neck Surgery and in the Department of Radiotherapy and Radiooncology at the Saarland University Medical Center of Homburg, Germany. The tumour was localized in the nasal cavity/paranasal sinuses (15) affecting the orbit twice and the nasopharynx (5). There were 14 patients with squamous cell carcinoma, 2 patients with mixed tumours and one patient with adenocarcinoma, adenoid cystic carcinoma, mucosal melanoma or plasmocytoma. The majority of the patients presented with advanced disease (T3 or T4 tumours). In 18/20 patients, brachytherapy was performed as a boost technique, in the remaining two solely because of a previous radiation series. All surgical interventions were performed endonasally. Three to six weeks after surgery, a cast of the nasal cavity was created under general anaesthesia. Subsequently, an individual brachytherapy silicon applicator with two to four plastic tubes was manufactured. The radiation therapy was applied using the Ir-192 high-dose-rate-afterloading method (total dose 10-20 Gy) in two to five sessions, additionally in 18/20 patients a percutaneous radiotherapy with a total dose of 30-60 Gy was applied. After a mean duration of follow-up of 2 years, 7/20 patients experienced a local progression, 5/19 a regional recurrence in the neck nodes and 4/19 distant metastases. The 2-year survival was 57.3 %. No serious complications were reported. The silicone applicator was well tolerated by all patients. Because of the complexity of the sinonasal anatomy with the finding of mainly advanced tumours, the presented individual silicone brachytherapy applicator has proven to be useful and meaningful for endocavitary brachytherapy of malignancies of the nasal cavities, paranasal sinuses and nasopharynx.

show abstract

“…Clinical results are summarized in Table 4. 71,72,78,[82][83][84][85][86][87][88][89][90] As can be observed, the outcome of patients treated with brachytherapy appears superior to that of patients treated with EBRT alone without increased toxicity. Of course, the difference may be due to a selection bias as T3 and T4 patients are not candidate to brachytherapy.…”

Section: Brachytherapymentioning

confidence: 88%

Review of photon and proton radiotherapy for skull base tumours

Fossati

Vavassori²,

Deantonio

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tAn extremely large variety of benign and malignant tumours occur at skull base; these tumour lesions are in the proximity to structures deputed to relevant physiologic functions, limiting extensive surgical approaches to this body district. Most recent progresses of surgery and radiotherapy have allowed to improve local control with acceptable rates of side effects. Various photon radiotherapy techniques are employed, including 3-dimensional conformal radiotherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy (SRT) and brachytherapy that is manly limited to the treatment of primary or recurrent nasopharyngeal carcinoma. Proton beam radiotherapy is also extensively used thanks to its physical characteristics. Our review, focusing in particular on meningioma, chordoma, and chondrosarcoma, suggests that proton therapy plays a major role in the treatment of malignant tumours whereas photon therapy still plays a relevant role in the treatment of benign tumour lesions.

show abstract

Local control in advanced cancer of the nasopharynx: Is a boost dose by endocavitary brachytherapy of prognostic significance?

Cited by 27 publications

References 19 publications

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

Customized individual applicators for endocavitary brachytherapy in patients with cancers of the nasal cavity, sinonasal region and nasopharynx

Review of photon and proton radiotherapy for skull base tumours

Contact Info

Product

Resources

About